arrow
J

Jun Pyo Kim

Sungkyunkwan University School of Medicine
H指数:25
被引数:2,169

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma eMTBR-tau243 and p-tau205 as T2 biomarkers for biological staging and prognosis in Alzheimer’s disease

血浆eMTBR-tau243和p-tau205作为阿尔茨海默病生物分期和预后的T2生物标志物

2026-10-190
OAAI
Biomarker-integrated prognostic stagings for Alzheimer’s Disease

阿尔茨海默病的生物标志物综合预后分期

2026-02-020
OAAI
Glymphatic dysfunction links vascular pathology to Alzheimer’s biomarkers and cognitive decline

淋巴功能障碍将血管病理学与阿尔茨海默氏症的生物标志物和认知能力下降联系起来

2026-01-290
OAAI
Double cutoff strategies for plasma pTau217 to predict Tau PET positivity across multiple assay platforms: Tau-enriched and Tau-scarce cohorts for cost-effective clinical use

血浆pTau217的双重截止策略,以预测跨多个测定平台的Tau PET阳性: Tau富集和Tau稀缺的队列,以实现具有成本效益的临床使用

2026-01-140
OAAI
Interplay between age, APOE Ɛ4 and the metabolome in plasma and brain in Alzheimer’s disease

年龄、APOE Ɛ4与血浆和脑代谢组在阿尔茨海默病中的相互作用

2025-10-310
OA
CT-derived brain volumes and plasma p-Tau217 for risk stratification of amyloid positivity in early-stage Alzheimer’s disease

CT衍生的脑容积和血浆p-Tau217用于早期阿尔茨海默病中淀粉样蛋白阳性的风险分层

2025-10-300
OAAI
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex

tau PET阳性率在伴有和不伴有认知障碍的个体中,随年龄、Aβ状态、APOE基因型和性别而变化。

2025-07-160
OA
CYP1B1-RMDN2 Alzheimer's disease endophenotype locus identified for cerebral tau PET
2024-09-200
OAAI